| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $60M |
Buys | $61,921,024 | 2 | 5 |
Sells | $204,009,299 | 39 | 95 |
| BAKER BROS. ADVISORS LP | director | 2 | $61.92M | 0 | $0 | $61.92M |
| Kelley Shannon T | General Counsel | 0 | $0 | 3 | $962,825 | $-962,825 |
| Huntsman Carole | Chief Commercial Officer | 0 | $0 | 3 | $2.13M | $-2.13M |
| Dier Mardi | SVP and CFO | 0 | $0 | 3 | $3.13M | $-3.13M |
| Levy Richard S | director | 0 | $0 | 1 | $4.43M | $-4.43M |
| CRAVES FRED B | director | 0 | $0 | 2 | $5.08M | $-5.08M |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 0 | $0 | 2 | $5.24M | $-5.24M |
| Daly James M | director | 0 | $0 | 1 | $5.38M | $-5.38M |
| Sibold William John | President and CEO | 0 | $0 | 4 | $8.45M | $-8.45M |
| BATE KENNETH | director | 0 | $0 | 3 | $18.81M | $-18.81M |
| Taub Rebecca | director | 0 | $0 | 9 | $48.6M | $-48.6M |
| FRIEDMAN PAUL A | director | 0 | $0 | 8 | $101.8M | $-101.8M |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Over the last 12 months, insiders at Madrigal Pharmaceuticals, Inc. have bought $61.92M and sold $204.01M worth of Madrigal Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Madrigal Pharmaceuticals, Inc. have bought $69.84M and sold $79.68M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $61.92M.
The last purchase of 59,901 shares for transaction amount of $23.07M was made by BAKER BROS. ADVISORS LP (director) on 2025‑08‑20.
| 2026-01-26 | Sale | Taub Rebecca | director | 647 0.0028% | $492.42 | $318,596 | -3.01% | |
| 2026-01-26 | Sale | Sibold William John | President and CEO | 1,577 0.0068% | $492.42 | $776,546 | -3.01% | |
| 2026-01-26 | Sale | Huntsman Carole | Chief Commercial Officer | 910 0.004% | $493.78 | $449,339 | -3.01% | |
| 2026-01-20 | Sale | Taub Rebecca | director | 2,238 0.0096% | $490.77 | $1.1M | -3.55% | |
| 2026-01-20 | Sale | Kelley Shannon T | General Counsel | 692 0.003% | $497.36 | $344,173 | -3.55% | |
| 2026-01-09 | Sale | Taub Rebecca | director | 18,650 0.0855% | $522.76 | $9.75M | -3.92% | |
| 2026-01-09 | Sale | FRIEDMAN PAUL A | director | 24,800 0.1137% | $522.71 | $12.96M | -3.92% | |
| 2025-12-10 | Sale | Taub Rebecca | director | 18,650 0.0838% | $552.15 | $10.3M | -8.60% | |
| 2025-12-10 | Sale | FRIEDMAN PAUL A | director | 24,800 0.1115% | $552.18 | $13.69M | -8.60% | |
| 2025-12-04 | Sale | Sibold William John | President and CEO | 2,400 0.0106% | $575.34 | $1.38M | -12.91% | |
| 2025-12-02 | Sale | Dier Mardi | EVP and CFO | 4,173 0.019% | $578.34 | $2.41M | -10.31% | |
| 2025-11-21 | Sale | Huntsman Carole | Chief Commercial Officer | 1,958 0.0089% | $553.11 | $1.08M | +0.82% | |
| 2025-11-13 | Sale | Levy Richard S | director | 8,500 0.0388% | $520.96 | $4.43M | +7.29% | |
| 2025-11-05 | Sale | BATE KENNETH | director | 16,575 0.086% | $484.30 | $8.03M | +14.40% | |
| 2025-09-09 | Sale | Sibold William John | President and CEO | 7,279 0.0324% | $445.63 | $3.24M | +9.60% | |
| 2025-08-21 | Sale | Sibold William John | President and CEO | 7,616 0.0336% | $400.18 | $3.05M | +19.06% | |
| 2025-08-20 | BAKER BROS. ADVISORS LP | director | 59,901 0.2643% | $385.16 | $23.07M | +23.48% | ||
| 2025-08-18 | Sale | Kelley Shannon T | General Counsel | 1,304 0.0055% | $367.81 | $479,627 | +22.72% | |
| 2025-08-18 | BAKER BROS. ADVISORS LP | director | 105,782 0.4453% | $367.26 | $38.85M | +22.72% | ||
| 2025-08-15 | Sale | BATE KENNETH | director | 10,000 0.0443% | $365.20 | $3.65M | +29.56% |
| BAKER BROS. ADVISORS LP | director | 1947968 8.577% | $949.28M | 11 | 0 | +28.98% |
| Taub Rebecca | director | 452704 1.9933% | $220.61M | 0 | 19 | |
| CRAVES FRED B | director | 350076 1.5414% | $170.6M | 1 | 10 | <0.0001% |
| FRIEDMAN PAUL A | director | 187164 0.8241% | $91.21M | 2 | 13 | <0.0001% |
| Sibold William John | President and CEO | 148497 0.6538% | $72.37M | 0 | 6 | |
| Levy Richard S | director | 21197 0.0933% | $10.33M | 3 | 5 | +602.61% |
| Dier Mardi | EVP and CFO | 10440 0.046% | $5.09M | 0 | 3 | |
| Huntsman Carole | Chief Commercial Officer | 9122 0.0402% | $4.45M | 0 | 5 | |
| Kelley Shannon T | General Counsel | 8481 0.0373% | $4.13M | 0 | 4 | |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 3728 0.0164% | $1.82M | 0 | 13 | |
| BATE KENNETH | director | 2627 0.0116% | $1.28M | 0 | 5 | |
| Daly James M | director | 1912 0.0084% | $931,755.84 | 0 | 3 | |
| Bahcall Safi R | President and CEO | 2053135 9.0401% | $1B | 12 | 0 | +16.52% |
| Gollust Keith R | director | 1539169 6.7771% | $750.07M | 13 | 7 | +9.47% |
| WILSON ROBERT N | director | 754118 3.3204% | $367.5M | 5 | 0 | <0.0001% |
| Chen Lan Bo | 620035 2.7301% | $302.16M | 1 | 0 | +32.54% | |
| Chen Lin Huey | 10 percent owner | 620035 2.7301% | $302.16M | 1 | 0 | +32.54% |
| Kovner Bruce | 340970 1.5013% | $166.16M | 51 | 21 | +19.69% | |
| BAY CITY CAPITAL LLC | 10 percent owner | 42875 0.1888% | $20.89M | 0 | 5 | |
| Schneebaum Marc R | Chief Financial Officer | 41668 0.1835% | $20.31M | 0 | 1 | |
| REARDON WILLIAM S | director | 36561 0.161% | $17.82M | 1 | 0 | +11.11% |
| Vukovic Vojo | SVP, Chief Medical Officer | 35249 0.1552% | $17.18M | 6 | 2 | +36.93% |
| BAILEY MICHAEL P | Sr. VP, Chief Comm. Officer | 29627 0.1304% | $14.44M | 0 | 1 | |
| Jacobson Eric W | Sr. VP, Research and CMO | 25300 0.1114% | $12.33M | 1 | 0 | |
| Rieder Wendy E | VP, IP and Legal, Gen. Counsel | 19823 0.0873% | $9.66M | 0 | 4 | |
| Ehrlich Keith S | VP, Fin. and Admin., CFO | 17573 0.0774% | $8.56M | 0 | 3 | |
| Chadwick Jeremy G | Sr. VP, Pgm Mgmt and Clin Ops | 15853 0.0698% | $7.73M | 0 | 1 | |
| Singh Amar | Sr. VP, Chief Business Officer | 15161 0.0668% | $7.39M | 0 | 1 | |
| Lynch Brian Joseph | SVP and General Counsel | 15001 0.0661% | $7.31M | 0 | 6 | |
| Koya Keizo | Sr. VP, Drug Development | 12999 0.0572% | $6.33M | 1 | 4 | +26.49% |
| Williams Martin D | Sr. VP, Business Dev., CBO | 200 0.0009% | $97,464.00 | 1 | 0 | |
| MILLIGAN DAVID V | director | 0 0% | $0 | 0 | 2 | |
| Sukhija Remy | Chief Commercial Officer | 0 0% | $0 | 0 | 1 |
Madrigal Pharmaceuticals, Inc. (MDGL) | $211,610,344 | 91 | 38.45% | $11.07B |
$2,765,836 | 72 | 20.00% | $11.52B | |
$108,876,545 | 67 | 72.81% | $9.46B | |
$88,307,390 | 38 | -1.70% | $10.21B | |
$19,233,721 | 36 | 70.14% | $11.82B | |
$1,801,511 | 23 | 18.58% | $8.92B | |
$415,090,639 | 19 | -14.04% | $14.62B | |
$143,065,458 | 17 | 8.01% | $19.45B | |
$11,859,102 | 17 | 18.62% | $8.15B | |
$1,279,017 | 16 | 51.12% | $9.24B | |
$627,701,115 | 15 | 145.68% | $11.67B | |
$284,820 | 10 | 45.67% | $13.18B | |
$11,898,979 | 10 | 54.58% | $8.35B | |
$948,235 | 8 | 15.56% | $9.15B | |
$105,414,951 | 5 | 10.07% | $7.43B | |
$40,276,273 | 4 | 34.57% | $19.38B | |
$41,376,000 | 4 | -12.07% | $7.57B | |
$36,900,000 | 3 | -9.12% | $11.26B | |
$999,989 | 1 | 262.16% | $17.16B |
| Increased Positions | 218 | +59.08% | 2M | +9.74% |
| Decreased Positions | 157 | -42.55% | 3M | -11.09% |
| New Positions | 86 | New | 615,180 | New |
| Sold Out Positions | 40 | Sold Out | 201,033 | Sold Out |
| Total Postitions | 430 | +16.53% | 24M | -1.35% |
| Baker Bros. Advisors Lp | $1.27M | 9.31% | 2.14M | +165,683 | +8.38% | 2025-09-30 |
| Rtw Investments, Lp | $1.18M | 8.67% | 1.99M | 0 | 0% | 2025-09-30 |
| Paulson & Co. Inc. | $1.13M | 8.29% | 1.91M | -182,000 | -8.71% | 2025-09-30 |
| Janus Henderson Group Plc | $1.09M | 8.01% | 1.84M | -349,063 | -15.93% | 2025-09-30 |
| Avoro Capital Advisors Llc | $1.09M | 7.97% | 1.83M | -42,000 | -2.24% | 2025-09-30 |
| Vanguard Group Inc | $1.08M | 7.88% | 1.81M | -65,227 | -3.48% | 2025-09-30 |
| Blackrock, Inc. | $926,266.00 | 6.78% | 1.56M | +120,988 | +8.41% | 2025-09-30 |
| State Street Corp | $390,824.00 | 2.86% | 658,097 | -32,618 | -4.72% | 2025-09-30 |
| Geode Capital Management, Llc | $265,004.00 | 1.94% | 446,233 | +31,841 | +7.68% | 2025-09-30 |
| William Blair Investment Management, Llc | $244,557.00 | 1.79% | 411,802 | +61,513 | +17.56% | 2025-09-30 |